OTC Markets OTCPK - Delayed Quote USD
Santhera Pharmaceuticals Holding AG (SPHDF)
14.75
0.00
(0.00%)
As of June 8 at 8:00:00 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
39,117
39,117
103,414
7,473
-1,595
Cost of Revenue
15,534
15,534
3,235
3,592
3,767
Gross Profit
23,583
23,583
100,179
3,881
-5,362
Operating Expense
56,734
56,734
49,018
55,857
51,526
Operating Income
-33,151
-33,151
51,161
-51,976
-56,888
Net Non Operating Interest Income Expense
-7,784
-7,784
-20,910
-20,342
-19,861
Pretax Income
-41,662
-41,662
54,820
-70,616
-54,717
Tax Provision
312
312
38
460
809
Net Income Common Stockholders
-41,974
-41,974
54,782
-71,076
-55,526
Diluted NI Available to Com Stockholders
-41,974
-41,974
54,782
-71,076
-55,526
Basic EPS
-3.69
--
5.18
-11.67
-16.20
Diluted EPS
-3.69
--
5.01
-11.67
-16.20
Basic Average Shares
11,387.07
--
10,578.75
6,092.73
3,416.99
Diluted Average Shares
11,387.07
--
10,923.66
6,092.73
3,416.99
Total Operating Income as Reported
-33,110
-33,110
68,844
-51,976
-56,888
Rent Expense Supplemental
--
--
--
165
190
Total Expenses
72,268
72,268
52,253
59,449
55,293
Net Income from Continuing & Discontinued Operation
-41,974
-41,974
54,782
-71,076
-55,526
Normalized Income
-38,719.35
-38,719.35
29,082.83
-72,836.46
-74,322.22
Interest Income
929
929
506
0
1
Interest Expense
7,776
7,776
21,314
20,189
16,423
Net Interest Income
-7,784
-7,784
-20,910
-20,342
-19,861
EBIT
-33,886
-33,886
76,134
-50,427
-38,294
EBITDA
-28,240
-28,240
79,178
-40,569
-34,570
Reconciled Cost of Revenue
15,534
15,534
3,235
3,592
3,767
Reconciled Depreciation
5,646
5,646
3,044
9,858
3,724
Net Income from Continuing Operation Net Minority Interest
-41,974
-41,974
54,782
-71,076
-55,526
Total Unusual Items Excluding Goodwill
-3,557
-3,557
25,717
1,924
22,095
Total Unusual Items
-3,557
-3,557
25,717
1,924
22,095
Normalized EBITDA
-24,683
-24,683
53,461
-42,493
-56,665
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-302.35
-302.35
17.83
163.54
3,298.78
12/31/2021 - 7/1/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade